

Docket No. PHUS-58

Applicants hereby traverse the restriction. Applicants note that the method of use requires administration of the claimed pharmaceutical composition and so is patentable therewith. Applicants further note that in the field of incontinence, the combined use of oxybutynin with darifenacin, duloxetine or tolterodine has not been known. This is because clinicians as a practice do not simultaneously prescribe two different anti-incontinence drugs; instead, they prescribe a first drug and then, if a patient does not respond well to the first drug, a second drug is prescribed, wherein the second drug is not taken with the first drug.


Applicants hereby withdraw claims 13-48, 64-74 and 106-122 from consideration without prejudice or waiver of the right to pursue said claims in this or another application. Applicants elect remaining claims 1-12 of Group I for further prosecution. Specifically, applicants elect a pharmaceutical composition comprising oxybutynin and a second drug selected from darifenacin, duloxetine or tolterodine. The composition also includes at least one pharmaceutical excipient. The elected species is supported by claims 1-12 and the specification as originally filed.

Enclosed herewith is an Amendment to the Claims.

In view of all the foregoing, Applicants submit that claims 1-12 are in form for allowance. An early notice of allowance thereof is respectfully requested.

Respectfully submitted,

Date: 12-17-03
Innovar, L.L.C.
P.O. Box 250647
Plano, TX 75025-0647
Phone: (972) 747-7373
Fax: (972) 747-7375


Rick Matos (Customer No. 24,039)
Agent for Applicants
Registration No. 40,082
Email: innovarllc@sbcglobal.net

Docket No. PHUS-58 AMENDMENT TO THE CLAIMS

-1-

CLAIMS

We claim the following:

- 1) (Previously Amended) A pharmaceutical composition comprising:
 - a) oxybutynin;
 - b) a second drug for treating incontinence, wherein the second drug is selected from the group consisting of darifenacin, duloxetine and tolterodine; and
 - c) at least one pharmaceutical excipient.
- 2) (Original) The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is present as a manufactured batch.
- 3) (Original) The pharmaceutical composition of claim 2 comprising:
 - a) a homogeneous mixture of oxybutynin, the second drug and at least one pharmaceutical excipient.
- 4) (Original) The pharmaceutical composition of claim 2 comprising:
 - a) a heterogeneous mixture of oxybutynin, the second drug and at least one pharmaceutical excipient.
- 5) (Original) The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is present as a unit dose.
- 6) (Original) The pharmaceutical composition of claim 5, wherein at least one of the oxybutynin and the second drug is present in a therapeutically effective amount.
- 7) (Original) The pharmaceutical composition of claim 5, wherein the oxybutynin and the second drug are each present in a therapeutically effective amount.
- 8) (Original) The pharmaceutical composition of claim 5, wherein at least one of the oxybutynin and the second drug is present in a sub-therapeutically effective amount.
- 9) (Original) The pharmaceutical composition of claim 5, wherein the oxybutynin and the second drug are present in sub-therapeutically effective amounts.
- 10) (Original) The pharmaceutical composition of claim 5 comprising:
 - a) a homogeneous mixture of oxybutynin, the second drug and at least one pharmaceutical excipient.
- 11) (Original) The pharmaceutical composition of claim 5 comprising:

Docket No. PHUS-58 AMENDMENT TO THE CLAIMS

-2-

a) a heterogeneous mixture of oxybutynin, the second drug and at least one pharmaceutical excipient.

12) (Original) The pharmaceutical composition of claim 1, 2 or 5, wherein the weight ratio of oxybutynin to second drug ranges from 1:0.1 to 1:20.

Claims 13-48 (Withdrawn)

Claims 49-63 (Cancelled)

Claims 64-74 (Withdrawn)

Claims 75-105 (Cancelled)

Claims 106-122 (Withdrawn)

Claims 123-132 (Cancelled)